Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 309-316

  Bilici, Ahmet ^a   Ustaalioglu, Bala Basak Oven ^a   Ercan, Serif ^a   Orcun, Asuman ^a   Seker, Mesut ^a   Salepci, Taflan ^a   Gumus, Mahmut ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Gastric cancer; Plasma M30 level; Plasma M65 levels; Survival

Indexed keywords

CYTOKERATIN 18; M30 PROTEIN; M65 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; M30 BLOOD LEVEL; M65 BLOOD LEVEL; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATIN-18; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960912819     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1480-0     Document Type: Article

References (26)

1. C Caulín GS Salvesen RG Oshima 1997 Caspase cleavage of keratin 18, reorganization of intermediate filaments during epithelial cell apoptosis J Cell Biol 138 1379 1394 9298992 10.1083/jcb.138.6.1379 (Pubitemid 27415063)
2. NO Ku J Liao MB Omary 1997 Apoptosis generates stable fragments of human type I keratins J Biol Chem 272 33197 33203 9407108 10.1074/jbc.272.52.33197 1:CAS:528:DyaK1cXps1Wl (Pubitemid 28023666)
3. K Bivén H Erdal M Hägg, et al. 2003 A novel assay for discovery, characterization of pro-apoptotic drugs, for monitoring apoptosis in patient sera Apoptosis 8 263 268 12766486 10.1023/A:1023672805949 (Pubitemid 36749611)
4. G Kramer H Erdal HJ Mertens, et al. 2004 Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18 Cancer Res 64 1751 1756 14996736 10.1158/0008-5472.CAN-03-2455 1:CAS:528:DC%2BD2cXhsleku7w%3D (Pubitemid 38428698)
5. T Ueno M Toi S Linder 2005 Detection of epithelial cell death in the body by cytokeratin 18 measurement Biomed Pharmacother 59 S359 S362 16507409 10.1016/S0753-3322(05)80078-2 1:CAS:528:DC%2BD28Xpt1Clsg%3D%3D
6. MP Leers W Kölgen V Björklund, et al. 1999 Immunocytochemical detection, mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis J Pathol 187 567 572 10398123 10.1002/(SICI)1096-9896(199904)187: 5<567::AID-PATH288>3.0.CO;2-J 1:CAS:528:DyaK1MXisFarsL4%3D (Pubitemid 29151999)
7. L Galluzzi MC Maiuri I Vitale H Zischka M Castedo L Zitvogel G Kroemer 2007 Cell death modalities: classification, pathophysiological implications Cell Death Differ 14 1237 1243 17431418 10.1038/sj.cdd.4402148 1:CAS:528: DC%2BD2sXms1Sqsrk%3D (Pubitemid 46969863)
8. Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M (2010) Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 10:719-722
9. M Demiray EE Ulukaya M Arslan, et al. 2006 Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study Cancer Invest 24 669 676 17118776 10.1080/07357900600981307 1:CAS:528: DC%2BD2sXptVWrtw%3D%3D (Pubitemid 44836170)
10. T Ueno M Toi K Bivén H Bando T Ogawa S Linder 2003 Measurement of an apoptotic product in the sera of breast cancer patients Eur J Cancer 39 769 774 12651202 10.1016/S0959-8049(02)00865-1 1:STN:280:DC%2BD3s7js1yiug%3D%3D (Pubitemid 36315993)
11. E Ulukaya A Yilmaztepe S Akgoz S Linder M Karadag 2007 The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer, helpful to predict the survival Lung Cancer 56 399 404 17316892 10.1016/j.lungcan.2007.01.015 (Pubitemid 46679086)
12. MH Olofsson T Ueno Y Pan, et al. 2007 Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy Clin Cancer Res 13 3198 3206 17545523 10.1158/1078-0432.CCR-07-0009 1:CAS:528:DC%2BD2sXmtVajurw%3D (Pubitemid 46944902)
13. B Ozturk U Coskun B Sancak E Yaman S Buyukberber M Benekli 2009 Elevated serum levels of M30, M65 in patients with locally advanced head, neck tumors Int Immunopharmacol 9 645 648 19249390 10.1016/j.intimp.2009.02.004 1:CAS:528:DC%2BD1MXksVWnt7c%3D
14. C Ausch V Buxhofer-Ausch U Olszewski W Hinterberger E Ogris R Schiessel G Hamilton 2009 Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients Eur J Surg Oncol 35 1164 1168 19254831 1:STN:280:DC%2BD1MnptlShsw%3D%3D
15. C Dive RA Smith E Garner, et al. 2010 Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer Br J Cancer 102 577 582 20051949 10.1038/sj.bjc.6605494 1:CAS:528:DC%2BC3cXhsVSrs7c%3D
16. EC de Haas A di Pietro, et al. 2008 Simpson KL,Clinical evaluation of M30, M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer Neoplasia 10 1041 1048 18813353
17. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
18. AM Desai M Pareek PG Nightingale JW Fielding 2004 Improving outcomes in gastric cancer over 20 years Gastric Cancer 7 196 201 15616767 10.1007/s10120-004-0289-0
19. G Galizia E Lieto M Orditura, et al. 2007 Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery World J Surg 31 1458 1468 17516110 10.1007/s00268-007-9016-4 (Pubitemid 46945355)
20. JG Kim SK Sohn YS Chae, et al. 2007 Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer Ann Oncol 18 1030 1036 17426061 10.1093/annonc/mdm085 1:STN:280: DC%2BD2szntVamtw%3D%3D (Pubitemid 47050494)
21. T Abe M Fukumoto K Tsuchiya, et al. 1989 Human monoclonal antibodies against cytokeratin 18 generated from patients with gastric cancer Jpn J Cancer Res 80 271 276 2470715 1:STN:280:DyaL1M3lsVyjtA%3D%3D (Pubitemid 20027220)
22. W Xu MW Zhang J Huang X Wang SF Xu Y Li SJ Wang 2005 Correlation between CK18 gene, gastric carcinoma micrometastasis World J Gastroenterol 11 6530 6534 16425429 1:CAS:528:DC%2BD28XhvVamtL4%3D (Pubitemid 43136894)
23. Greene FLPD, Fleming ID (2002) American joint committee on cancer staging manual, 6th edn. Springer, Philadelphia
24. YX Wu JH Wang H Wang XY Yang 2003 Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma, their correlation with prognosis Zhonghua Bing Li Xue Za Zhi 32 314 318 14514374 (article in Chinese)
25. JM Hou A Greystoke L Lancashire, et al. 2009 Evaluation of circulating tumor cells, serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy Am J Pathol 175 808 816 19628770 10.2353/ajpath.2009.090078 1:CAS:528:DC%2BD1MXhtVGqt7%2FI
26. C Ausch V Buxhofer-Ausch U Olszewski R Schiessel E Ogris W Hinterberger G Hamilton 2009 Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients J Gastrointest Surg 13 2020 2026 19727975 10.1007/s11605-009-0992-6